JPWO2021121367A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021121367A5 JPWO2021121367A5 JP2022537297A JP2022537297A JPWO2021121367A5 JP WO2021121367 A5 JPWO2021121367 A5 JP WO2021121367A5 JP 2022537297 A JP2022537297 A JP 2022537297A JP 2022537297 A JP2022537297 A JP 2022537297A JP WO2021121367 A5 JPWO2021121367 A5 JP WO2021121367A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- lung cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102000008300 Mutant Proteins Human genes 0.000 claims 3
- 108010021466 Mutant Proteins Proteins 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 102200006538 rs121913530 Human genes 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/126687 | 2019-12-19 | ||
| CN2019126687 | 2019-12-19 | ||
| CNPCT/CN2020/070885 | 2020-01-08 | ||
| CN2020070885 | 2020-01-08 | ||
| CNPCT/CN2020/073723 | 2020-01-22 | ||
| CN2020073723 | 2020-01-22 | ||
| CNPCT/CN2020/078565 | 2020-03-10 | ||
| CN2020078565 | 2020-03-10 | ||
| PCT/CN2020/137497 WO2021121367A1 (en) | 2019-12-19 | 2020-12-18 | Kras mutant protein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506532A JP2023506532A (ja) | 2023-02-16 |
| JPWO2021121367A5 true JPWO2021121367A5 (ru) | 2023-12-25 |
Family
ID=76478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537297A Pending JP2023506532A (ja) | 2019-12-19 | 2020-12-18 | Ｋｒａｓ突然変異型タンパク質阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11180506B2 (ru) |
| EP (1) | EP4077326A4 (ru) |
| JP (1) | JP2023506532A (ru) |
| KR (1) | KR20220119088A (ru) |
| CN (4) | CN113651814B (ru) |
| AU (1) | AU2020404319A1 (ru) |
| BR (1) | BR112022011421A2 (ru) |
| CA (1) | CA3165238A1 (ru) |
| CL (1) | CL2022001670A1 (ru) |
| CO (1) | CO2022010098A2 (ru) |
| CR (1) | CR20220351A (ru) |
| IL (1) | IL293962A (ru) |
| MX (1) | MX2022007527A (ru) |
| PE (1) | PE20230161A1 (ru) |
| TW (1) | TW202128691A (ru) |
| WO (1) | WO2021121367A1 (ru) |
| ZA (2) | ZA202207450B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2020156285A1 (zh) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
| CN113651814B (zh) * | 2019-12-19 | 2022-06-17 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| MX2022007515A (es) | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
| AR125835A1 (es) * | 2021-05-12 | 2023-08-16 | Jacobio Pharmaceuticals Co Ltd | Novedosas formas del compuesto i y uso de las mismas |
| KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| CN115894520A (zh) * | 2021-09-23 | 2023-04-04 | 上海和誉生物医药科技有限公司 | 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110036010A (zh) * | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| EP3573967A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| CN111989321B (zh) * | 2017-11-15 | 2024-05-14 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
| US11453667B2 (en) * | 2018-01-19 | 2022-09-27 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor |
| MA52780A (fr) * | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| MA51848A (fr) * | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CN113651814B (zh) * | 2019-12-19 | 2022-06-17 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
-
2020
- 2020-12-18 CN CN202111058976.0A patent/CN113651814B/zh active Active
- 2020-12-18 CR CR20220351A patent/CR20220351A/es unknown
- 2020-12-18 KR KR1020227024638A patent/KR20220119088A/ko unknown
- 2020-12-18 IL IL293962A patent/IL293962A/en unknown
- 2020-12-18 TW TW109145045A patent/TW202128691A/zh unknown
- 2020-12-18 JP JP2022537297A patent/JP2023506532A/ja active Pending
- 2020-12-18 CA CA3165238A patent/CA3165238A1/en active Pending
- 2020-12-18 EP EP20903388.5A patent/EP4077326A4/en active Pending
- 2020-12-18 AU AU2020404319A patent/AU2020404319A1/en active Pending
- 2020-12-18 PE PE2022001137A patent/PE20230161A1/es unknown
- 2020-12-18 BR BR112022011421A patent/BR112022011421A2/pt unknown
- 2020-12-18 CN CN202111617953.9A patent/CN114349750A/zh active Pending
- 2020-12-18 CN CN202210597916.4A patent/CN115192577B/zh active Active
- 2020-12-18 MX MX2022007527A patent/MX2022007527A/es unknown
- 2020-12-18 CN CN202080014581.8A patent/CN113454083A/zh active Pending
- 2020-12-18 WO PCT/CN2020/137497 patent/WO2021121367A1/en unknown
-
2021
- 2021-03-10 US US17/197,095 patent/US11180506B2/en active Active
- 2021-08-20 US US17/407,418 patent/US11787811B2/en active Active
- 2021-12-27 US US17/562,492 patent/US20220213109A1/en active Pending
-
2022
- 2022-06-17 CL CL2022001670A patent/CL2022001670A1/es unknown
- 2022-07-05 ZA ZA2022/07450A patent/ZA202207450B/en unknown
- 2022-07-18 CO CONC2022/0010098A patent/CO2022010098A2/es unknown
- 2022-08-05 ZA ZA2022/08783A patent/ZA202208783B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021121367A5 (ru) | ||
| JP2021098728A5 (ru) | ||
| JP2022121594A5 (ru) | ||
| JP2024023189A5 (ru) | ||
| JP2022191257A5 (ru) | ||
| JP2018109022A5 (ru) | ||
| JP2015523397A5 (ru) | ||
| JPWO2019213516A5 (ru) | ||
| JP2006523216A5 (ru) | ||
| JP2018533560A5 (ru) | ||
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| JP2020521797A5 (ru) | ||
| JP2014525454A5 (ru) | ||
| JP2023537600A (ja) | がんを処置するための複製ストレス経路剤組成物および方法 | |
| JP2019533660A5 (ru) | ||
| JP2019524888A5 (ru) | ||
| JP2019536790A5 (ru) | ||
| JP2013528215A5 (ru) | ||
| JP2021504384A5 (ru) | ||
| RU2020108192A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf | |
| JP2016502540A5 (ru) | ||
| BR112019026029A2 (pt) | Formulações farmacêuticas orais de remogliflozina | |
| RU2017124612A (ru) | Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр | |
| JP2021503448A5 (ru) | ||
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина |